Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00062140 | Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00112567 | Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 |
| clinicaltrials |
| NCT00107354 | Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant | completed | Phase 1 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 20, 2010 | clinicaltrials |
| NCT00049634 | Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder | completed | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2010 | clinicaltrials |
| NCT00279773 | Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 | 34 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 30, 2010 | clinicaltrials |
| NCT00005593 | Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 31 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 11, 2010 | clinicaltrials |
| NCT00054340 | Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2010 | clinicaltrials |
| NCT00118326 | Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2010 | clinicaltrials |
| NCT00293410 | Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders | completed | Phase 1 | 70 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2010 | clinicaltrials |
| NCT00010283 | Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00255710 | Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer | completed | Phase 1 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 17, 2010 | clinicaltrials |
| NCT00003082 | Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer | completed | Phase 1 | 27 | University of ArizonaOTHER | 1 | Mar 16, 2010 | clinicaltrials |
| NCT00003243 | Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00004871 | Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00006042 | Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00015925 | MS-275 in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00077558 | 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT00834002 | Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission(CCRG 05-001) | completed | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Feb 9, 2010 | clinicaltrials |
| NCT00004058 | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder | terminated | Phase 1 | — | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jan 26, 2010 | clinicaltrials |
| NCT00401739 | Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | completed | Phase 1 | 40 | CSL LimitedINDUSTRY | 1 | Sep 16, 2009 | clinicaltrials |
| NCT00530699 | Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 1 | Sep 11, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | May 5, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 54 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2009 | clinicaltrials |
| NCT00667927 | Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission | completed | Phase 1 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2008 | clinicaltrials |
| NCT00129168 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 100 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00233909 | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 55 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00001748 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00274248 | MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia | completed | Phase 1 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00104468 | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 50 | SGX Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 17, 2008 | clinicaltrials |
| NCT00126893 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | terminated | Phase 1 | 36 | Celgene CorporationINDUSTRY | 1 | May 15, 2007 | clinicaltrials |
| NCT00299780 | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. | completed | Phase 1 | 12 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2007 | clinicaltrials |
| NCT00460447 | Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | University Hospital Carl Gustav CarusOTHER | 1 | Apr 16, 2007 | clinicaltrials |
| NCT00089596 | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers | completed | Phase 1 / Phase 2 | 10 | ViaCellINDUSTRY | 1 | Apr 12, 2007 | clinicaltrials |
| NCT00219765 | Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients | terminated | Phase 1 / Phase 2 | 30 | Poitiers University HospitalOTHER | 1 | Nov 28, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 21, 2010source: clinicaltrials